Supplements

MS Highlights From the AAN & CMSC Annual Meetings

Publish date: September 17, 2020

 

This supplement to Neurology Reviews compiles MS-related news briefs from the 2020 virtual annual meetings of the American Academy of Neurology and the Consortium of Multiple Sclerosis Centers.

Click here to read the supplement

Recommended Reading

Smoking increases risk of high plasma NfL levels in patients with MS
MDedge Neurology
In MS, serious adverse effects are more common in rituximab versus ocrelizumab
MDedge Neurology
Exposure to DMT may delay disability accumulation in primary progressive MS
MDedge Neurology
Lessons for patients with MS and COVID-19
MDedge Neurology
Cardiovascular risk factors linked to brain atrophy in MS
MDedge Neurology
Satralizumab reduces risk of severe NMOSD relapse
MDedge Neurology
App for MS aims to capture elusive signals of progression
MDedge Neurology
High plasma GFAP level predicts disability accumulation in secondary progressive MS
MDedge Neurology
Multiple sclerosis prodrome holds promise of earlier diagnosis
MDedge Neurology
Masitinib impresses in nonactive progressive MS
MDedge Neurology